Boron neutron capture therapy (BNCT) is a promising therapy for malignant tumors that requires selective and high concentrations of B accumulation in tumor cells. Despite ongoing developments in novel boron agents and delivery carriers, the progress and clinical application of BNCT is still restricted by the low B accumulation and tumor-to-normal tissue (T/N) ratio. Herein, a dissolving microneedle-based transdermal drug delivery system was specifically designed for BNCT in a mouse model of melanoma.
View Article and Find Full Text PDF